Immunotech Laboratories, Inc.

Equities

IMMB

US45254F2039

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 02:01:22 2024-03-18 pm EDT			5-day change	1st Jan Change
0.0001 ^USD	-.--%		-.--%	-.--%

2017	Immunotech Laboratories, Inc. Announces Addition of Hongxiang Hui to Advisory Board	CI
2017	Immunotech Laboratories Enters Distribution Agreement for the Territory of the Ukraine; Enters Final Step of Full Commercialization by the BDA Post Phase 3 Approval of ITV-1 for HIV/AIDS	CI

Immunotech Laboratories, Inc. cancelled the transaction announced on October 1, 2013

October 30, 2016

Immunotech Laboratories, Inc. (OTCPK:IMMB) announced that it has entered into equity line agreement with World Finance Capital Holdings Inc on October 1, 2013. The investor will provide SWORD financing to the company. As of October 1, 2016, Immunotech Laboratories, Inc. (OTCPK:IMMB) cancelled the transaction.

Latest news about Immunotech Laboratories, Inc.

Immunotech Laboratories, Inc. Announces Addition of Hongxiang Hui to Advisory Board	17-12-22	CI
Immunotech Laboratories Enters Distribution Agreement for the Territory of the Ukraine; Enters Final Step of Full Commercialization by the BDA Post Phase 3 Approval of ITV-1 for HIV/AIDS	17-06-22	CI
Eco-Petroleum Solutions, Inc. acquired Immunotech Laboratories, Inc..	17-06-13	CI
Immunotech Laboratories, Inc. cancelled the transaction announced on October 1, 2013	16-09-30	CI
Ebola becomes latest stock scam, SEC says	14-11-20	RE
Immunotech Laboratories, Inc. and Immunotech Laboratories, BG Enter into Agreement with Uldic Investment to Market Potential Ebola Virus Disease Treatment in Africa	14-10-21	CI
Immunotech Laboratories, Inc and Immunotech Laboratories, BG. Announces Successful Completion of Phase I and Phase II Field Trials of HIV/AIDS and Hepatitis C Virus Treatment	14-10-07	CI
Immunotech Laboratories, Inc. Announces Completion of Phase I and Phase II Field Trials of Patented Treatment of the HIV/AIDS and Hepatitis C Viruses	14-08-28	CI
Immunotech Laboratories, Inc. announced that it expects to receive funding from World Finance Capital Holdings Inc.	13-10-01	CI
Immunotech Laboratories, Inc. Appoints Blaine Nabors as VP of Business Development	13-04-15	CI
Immunotech Laboratories, Inc. Relocates to New Research & Development Laboratory Facility	13-03-01	CI
Immunotech Laboratories, Inc. Announces Clinical Trials Updates for company's AIDS-HIV 'IPF' Medicines	13-02-20	CI
Immunotech Laboratories, Inc. Appoints Valentin Dimitrov to Board of Directors	13-02-04	CI
Immunotech Laboratories, Inc. Appoints Bo Linton as Director	12-10-11	CI
Immunotech Laboratories, Inc. Announces Resignation of Ara Ghanime as Director	12-09-19	CI

Chart Immunotech Laboratories, Inc.

Duration

Period

More charts

Company Profile

Immunotech Laboratories, Inc. (Immunotech) is a drug development company that focuses on research and development in the biotechnology field. The Company is also focused on the commercialization of its proprietary proteins known as Irreversible Pepsin Fraction (IPF) ITV-1 for the treatment of debilitating infectious diseases, such as human immunodeficiency virus (HIV) and Hepatitis Type C.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IMMUNOTECH LABORATORIES, INC.	-.--%	57.5K
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	102B
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.29B
ARGENX SE	+1.46%	22.18B
BIONTECH SE	-16.67%	21.2B
GENMAB A/S	-8.58%	18.31B
WUXI APPTEC CO., LTD.	-38.74%	17.38B
BEIGENE, LTD.	-13.21%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.97B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs